

AD _____

Award Number: **W81XWH-10-1-0228**

TITLE: Optimizing Treatment of Advanced Prostate Cancer and Exploiting Mechanisms Driving Castration Resistance

PRINCIPAL INVESTIGATOR: **Elahe A. Mostaghel, M.D. Ph.D**

CONTRACTING ORGANIZATION:
**Fred Hutchinson Cancer Research Center
Seattle, WA 98109**

REPORT DATE: **April 2011**

TYPE OF REPORT: **Annual**

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 04/30/2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 01 Apr 2010 - 31 Mar 2011	
4. TITLE AND SUBTITLE Optimizing Treatment of Advanced Prostate Cancer and Exploiting Mechanisms Driving Castration Resistance			5a. CONTRACT NUMBER W81XWH-10-1-0228		
			5b. GRANT NUMBER PC094259		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Elahe Mostaghel, MD, PhD emostagh@fhcrc.org			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center PO Box 19024, D4-100 1100 Fairview Ave N Seattle, WA 98109-1024			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) US Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Castration resistant prostate cancer (CRPC) ubiquitously displays increased expression of the AR and AR target genes, reflecting the critical importance of this pathway in prostate cancer progression. As novel agents which potentially inhibit the AR pathway become clinically available, it will be critical to understand how severe shutdown of the AR pathway impacts tumor cell biology and how this will alter the natural history of CRPC. This proposal investigates the impact of maximal intra-tumoral androgen pathway suppression on prostate tumor regression and recurrence, and seeks to determine whether specific resistance mechanisms identified at tumor progression will reflect the efficacy of an androgen axis suppression and/or predict sensitivity to subsequent therapy. Our studies assess whether tumors recurring after the most stringent AR pathway blockade pharmacologically available will continue to retain a dependence on the AR axis or will exhibit an AR 'null' phenotype driven by non-AR directed resistance mechanisms. To date we have completed enrollment into our xenograft study of maximal androgen suppression, which uses the well defined LuCaP35 prostate cancer xenograft and three tiers of progressive AR axis suppression, as well as enrollment into one of two studies of high dose testosterone replacement therapy. Analysis of tumor growth and regression, as well as molecular analyses are ongoing and will be reported in years 2 and 3 of the award as per the Statement of Work.					
15. SUBJECT TERMS Castration resistant, intra-tumoral androgen, high dose testosterone					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 6	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusion.....	6

INTRODUCTION

Castration resistant prostate cancer (CRPC) ubiquitously displays increased expression of the AR and AR target genes, reflecting the critical importance of this pathway in prostate cancer progression. This proposal investigates the impact of maximal intra-tumoral androgen pathway suppression on prostate tumor regression and recurrence, and seeks to determine whether specific resistance mechanisms identified at tumor progression will reflect the efficacy of androgen axis suppression and/or predict sensitivity to subsequent therapy. Our studies will assess whether tumors recurring after the most stringent AR pathway blockade pharmacologically available will continue to retain a dependence on the AR axis or will exhibit an AR 'null' phenotype driven by non-AR directed resistance mechanisms. As novel agents which potentially inhibit the AR pathway become clinically available, it will be critical to understand how severe shutdown of the AR pathway impacts tumor cell biology and how this will alter the natural history of CRPC.


BODY

The primary research accomplishments associated with the Statement of Work for year one (months 1-12) are completion and/or initiation of the animal studies as listed in Technical Objectives 1 and 3 below. This report will detail the enrollment data for four of the five xenograft studies comprising this award (the fifth study will be performed during months 20-30 of the award). Evaluation of growth endpoints and molecular analyses have been initiated and will be further carried out and reported in years two and three of the award as per Technical Objectives 2 and 3 in the Statement of Work.

Technical Objective 1. Xenograft Studies of Maximal Androgen Suppression

- 1.1. castration (n=50 mice) months 1-12
- 1.2. castration+Casodex+Dutasteride+Ketoconazole (n=50 mice) months 1-18
- 1.3. castration+Vn-124 (n=50 mice) months 1-18

1.1 Enrollment into the castration only control arm has been completed, including n=5 tumors each harvested at days 7 and 21 after castration, and n=33 tumors harvested following castration recurrent re-growth (defined as re-growth to 750mm³). Preliminary analyses demonstrate an engraftment rate of 83% (predicted rate 80%), and that 65% of tumors recurred by day 200 following castration, thereby meeting the 60% incidence of re-growth in the control group that had been assumed for the power calculations (section 6a. in the ACURO animal appendix for these studies).



1.2 and 1.3. The second arm of this study comprises maximal pharmacologic suppression of the androgen axis with currently available agents. This includes the CYP17A inhibition with ketoconazole, SRD5A1 and 2 inhibition with dutasteride, and the AR inhibition with the antiandrogen bicalutamide. Enrollment into this study has been completed, with n=5 and n=4 tumors harvested at the day 7 and day 21 time points, respectively, and n=32 tumors enrolled in

the long term treatment group. Tumor growth and regression data are still being collated and will be complete by month 18 as denoted in the SOW. The third arm of this study comprises treatment with the novel agent VN-124, which is a combined CYP17A inhibitor and androgen receptor antagonists. Enrollment into this study is presently ongoing and will be complete by month 18 as denoted in the SOW.


Technical Objective 3. Xenograft Studies of Testosterone Replacement

3a. Cohort 1 study with 4 arm randomization (n=100 mice), months 1-12

1. Placebo/vehicle control (n=20)
2. Testosterone low 5mg/kg/day (n=20)
3. Testosterone low + dutasteride (n=20)
4. Testosterone high 100mg/kg/day (n=20)

The goal of the studies in this Objective is to evaluate the differential sensitivity of tumors recurring after progressive AR inhibition to the repressive effects of supra-physiologic T replacement. Two studies are to be performed. The first study will evaluate the impact of testosterone treatment on the castration recurrent xenograft LuCaP 35V (Technical Objective 3a). The second study (Technical Objective 3b, in months 20-30) will be done with a LuCaP35V line that has been subjected to additional AR pathway inhibition and has then subsequently recurred as a 'super-resistant' line.

Pilot study to confirm appropriateness of testosterone dosing strategy. Prior to enrolling mice into the Cohort 1 study of testosterone replacement, a small pilot study using the proposed treatment regimens was performed to ensure that the replacement doses were yielding the desired serum testosterone levels. Due to baseline variability in circulating androgen levels, all mice were to be castrated and then treated with stepped doses of testosterone with or w/out dutasteride to yield either physiologic androgen levels, or the supra-physiologic androgen levels predicted to be necessary to cause testosterone-mediated growth inhibition. Five non-tumor bearing mice were serially treated with testosterone propionate i.p. according to the schema in Figure 2.



Measurements of serum androgen levels by mass spectroscopy are presented in Table 1 (below) and demonstrate achievement of physiologic serum T levels in the Low T + Dutasteride cohort (3.85 ng/ml +/- 0.84), and supra-physiologic levels in the High T cohort (75.1 ng/ml +/- 10.8).

3a. Enrollment into Cohort 1 has nearly been completed. To date n=20 mice have been enrolled into the no treatment control arm, and n=16 have been enrolled into each of the remaining 3 testosterone treatment arms. Completion of enrollment into this study is anticipated in the next month.

Table 1. Serum T levels after Low and High dose T replacement									
time point	serum T (ng/ml)	mouse number					average (stdev)		
		1	2	3	4	5			
0	Pre-Castration	9.19	2.47	7.23	5.34	7.21	6.29	2.53	
1	Castration	0.01	0.01	0.01	0.02	0.01	0.01	0.01	
2	Low T	0.95	0.75	1.09	0.73	0.79	0.86	0.15	
3	Low T + Dut	3.71		4.37	4.62	2.73	3.85	0.84	
4	High T	62.9		88.8	77.1	71.6	75.1	10.8	
5	Recovery	0.11	0.07		0.14	0.05	0.09	0.04	

KEY RESEARCH ACCOMPLISHMENTS

- Enrollment into 3 xenograft studies which will evaluate the impact of maximal androgen suppression on castration recurrent prostate cancer growth
- Confirmation of anticipated serum testosterone levels after low and high dose testosterone replacement therapy
- Enrollment into a 4 arm study which will assess the sensitivity of CRPC to physiologic and supra-physiologic testosterone replacement therapy
- Ongoing collection of tumor growth and regression data, and of tumor tissue for molecular studies

REPORTABLE OUTCOMES

A tissue repository comprising fixed and frozen tissues from the above xenograft studies is being generated. The fixed tissues will additionally be used to generate a tissue microarray resource.

CONCLUSION

As discussed, the primary research accomplishments associated with the Statement of Work for year one are completion and/or initiation of the animal studies. To date, analysis of these studies is ongoing and thus presentation of results or implications of the completed research is not yet available. We anticipate these studies will yield novel data on the ability of maximal pharmacologic androgen suppression to impact tumor androgen levels and castration recurrent growth, as well as the impact of supra-physiologic testosterone treatment on CRPC growth inhibition.